Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Fusidic acid – topical

Classification: B

Drug products: Fucidin, Fucidin®, Fucidin®-Hydrocortison, Fucidine, Fucidin-Hydrocortison, Fucithalmic, Fucithalmic®, Fusidinsyra/Betametason Ebb, Fusidinsyra/Betametason LEO, Fusidinsyra/Hydrokortison 2care4

ATC code: D06AX01, D07CA01, D07CC01, S01AA13

Summary

Published controlled studies on differences between men and women on efficacy, safety and pharmacokinetics for topical fusidic acid are lacking.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of topical fusidic acid have been found.

Effects

No studies with a clinically relevant sex analysis regarding the effects of topical fusidic acid have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of topical fusidic acid have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Other information

A retrospective analysis of patients with eczema or psoriasis on standard dermatological treatment (295 men, 291 women) found that significantly more men than women (79; 63%, 47; 37%) were administered whole-body UV treatment. Also, the results indicated that men had more treatments appointments per individual than women. Women were prescribed more emollients than men [1].

Updated: 2022-09-13

Date of litterature search: 2022-06-29

References

  1. Nyberg F, Osika I, Evengård B. "The Laundry Bag Project"--unequal distribution of dermatological healthcare resources for male and female psoriatic patients in Sweden. Int J Dermatol. 2008;47:144-9. PubMed
  2. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.] länk

Authors: Linnéa Karlsson Lind

Reviewed by: Diana Rydberg

Approved by: Karin Schenck-Gustafsson